[1]侯亚坤,黄 新,周星宇,等.内分泌治疗在根治性前列腺癌切除术后病理特征阴性患者中的临床疗效[J].医学信息,2024,37(01):158-162.[doi:10.3969/j.issn.1006-1959.2024.01.028]
　HOU Ya-kun,HUANG Xin,ZHOU Xing-yu,et al.Clinical Efficacy of Endocrine Therapy in Patients with Negative Pathological Features After Radical Prostatectomy[J].Journal of Medical Information,2024,37(01):158-162.[doi:10.3969/j.issn.1006-1959.2024.01.028]
点击复制

内分泌治疗在根治性前列腺癌切除术后病理特征阴性患者中的临床疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年01期
页码:
158-162
栏目:
论著
出版日期:
2024-01-01

文章信息/Info

Title:
Clinical Efficacy of Endocrine Therapy in Patients with Negative Pathological Features After Radical Prostatectomy
文章编号:
1006-1959（2024）01-0158-05
作者:
侯亚坤; 黄 新; 周星宇; 等
（新疆医科大学第一附属医院泌尿外科，新疆 乌鲁木齐 830054）
Author(s):
HOU Ya-kun; HUANG Xin; ZHOU Xing-yu; et al.
(Department of Urinary Surgery,the First Affiliated Hospital of Xinjiang Medical University,Urumqi 830054,Xinjiang,China)
关键词:
高危前列腺癌; 腹腔镜下前列腺癌根治术; 病理特征阴性; 内分泌治疗
Keywords:
High-risk prostate cancer; Laparoscopic radical prostatectomy; Negative pathological features; Endocrine therapy
分类号:
R737.25
DOI:
10.3969/j.issn.1006-1959.2024.01.028
文献标志码:
A
摘要:
目的 探讨局限性高危型根治性前列腺癌切除术后同时满足病理分期＜T3、淋巴结阴性、切缘阴性、脉管侵犯阴性及术后即刻患者PSA降至＜0.1 ng/ml患者内分泌治疗的效果。方法 回顾性分析我院2016年1月-2022年12月行腹腔镜下根治性前列腺癌切除术且术后病理特征同时满足病理分期＜T3、淋巴结阴性、切缘阴性、脉管侵犯阴性及术后即刻患者PSA降至＜0.1 ng/ml的90例局限性高危型前列腺癌患者，根据不同治疗方案分为腹腔镜下前列腺癌根治术+内分泌治疗（RP+ADT）组和腹腔镜下前列腺癌根治术后随访（RP）组，每组45例。比较两组总生化复发率、1年、2年、3年生化复发率、PSA无进展生存期，内分泌治疗不良反应。结果 两组总生化复发率、1年、2年、3年生化复发率、PSA无进展生存期比较，差异均无统计学意义（P＞0.05），RP+ADT组内分泌治疗后1例术后轻度肉眼血尿，1个月后自愈，13例潮热，3例肝毒性（轻度转氨酶升高），1例骨质疏松，1例脑梗死亡。内分泌治疗不良反应例数较少无法进行统计学分析。结论 对于病理特征同时满足病理分期＜T3、淋巴结阴性、切缘阴性、脉管侵犯阴性及术后即刻患者PSA降至＜0.1 ng/ml的局限性高危型前列腺癌术后患者推荐术后3年内随访观察，3年后根据患者PSA上升情况决定后续治疗。
Abstract:
Objective To investigate the effect of endocrine therapy in patients with pathological stage 0.05). In the RP+ADT group, 1 case had mild gross hematuria after endocrine therapy, and recovered after 1 month; 13 cases had hot flashes, 3 cases had hepatotoxicity (mild transaminase elevation), 1 case had osteoporosis and 1 case had cerebral infarction. The number of adverse reactions of endocrine therapy was small and could not be statistically analyzed.Conclusion For patients with localized high-risk prostate cancer whose pathological features meet the pathological stage

参考文献/References:

[1]韩苏军,刘飞,邢念增.1988-2015年中国肿瘤登记地区前列腺癌发病趋势分析[J].中华泌尿外科杂志,2022,43(1):51-55.[2]Mohler JL,Antonarakis ES,Armstrong AJ,et al.Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2019,17(5):479-505.[3]华俊,宋彦平,杨媛媛,等.前列腺特异性膜抗原PET/CT对中高危前列腺癌初始TNM分期及临床治疗策略的影响[J].中国肿瘤临床,2022,49(16):828-833.[4]李敏,王航,张道秀,等.老年前列腺癌行机器人辅助腹腔镜前列腺癌根治术的疗效分析[J].实用癌症杂志,2023,38(4):653-656.[5]张连栋,李和程,唐骁爽,等.盆腔淋巴结清扫数量与高危前列腺癌——文献回顾及基于单中心的初步研究[J].现代泌尿外科杂志,2019,24(7):543-546.[6]王超,平季根,陆勇,等.腹腔镜前列腺癌根治术+扩大盆腔淋巴结清扫治疗高危前列腺癌临床体会[J].现代泌尿生殖肿瘤杂志,2018,10(5):291-294.[7]高新,江东根,黄群雄,等.根治性前列腺切除联合扩大盆腔淋巴结清扫术治疗局部高危前列腺癌12年经验总结[J].中华泌尿外科杂志,2017,38(6):433-437.[8]Bandini M,Fossati N,Gandaglia G,et al.Neoadjuvant and adjuvant treatment in high-risk prostate cancer[J].Expert Rev Clin Pharmacol,2018,11(4):425-438.[9]Kroepfl D,Loewen H,Roggenbuck U,et al.Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy[J].BJU Int,2006,97(5):985-991.[10]双卫兵,夏漫城.前列腺癌根治术相关内分泌治疗[J].现代泌尿生殖肿瘤杂志,2018,10(3):189-191.[11]Wirth MP,Weissbach L,Marx FJ,et al.Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer[J].Eur Urol,2004,45(3):267-270.[12]Messing EM,Manola J,Yao J,et al.Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy[J].Lancet Oncol,2006,7(6):472-479.[13]McLeod DG,Iversen P,See WA,et al.Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer[J].BJU Int,2006,97(2):247-254.[14]陈志雄,李黎明,刘晓龙,等.晚期前列腺癌间歇性和持续性内分泌治疗的效果比较及生活质量分析[J].山东医药,2015(25):75-77.[15]张文陆,张旭.前列腺癌患者内分泌治疗后代谢异常及生活质量分析[J].黑龙江医药科学,2020,43(2):21-22.[16]Bosco C,Bosnyak Z,Malmberg A,Adolfsson J,et al.Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis[J].Eur Urol,2015,68(3):386-396.[17]谷伟军,陆菊明.前列腺癌雄激素剥夺治疗与动脉粥样硬化的代谢风险[J].中华内分泌代谢杂志,2008,24(5):571-573.[18]Morgia G,Russo GI,Tubaro A,et al.Prevalence of Cardiovascular Disease and Osteoporosis During Androgen Deprivation Therapy Prescription Discordant to EAU Guidelines: Results From a Multicenter, Cross-sectional Analysis From the CHOsIng Treatment for Prostate canCEr (CHOICE) Study[J].Urology,2016,96:165-170.[19]Dell’Oglio P,Bishr M,Boehm K,et al.Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer[J].Eur Urol Focus,2018,4(6):834-841.[20]黄丽,张庆,陈海燕.风险预防干预对前列腺癌患者术后并发症及生活质量的影响[J].癌症进展,2023,21(8):922-925.

更新日期/Last Update: 1900-01-01